scholarly journals Management of oral Kaposi’s sarcoma lesions on HIV-positive patient using highly active antiretroviral therapy: Case report and a review of the literature

2005 ◽  
Vol 41 (9) ◽  
pp. 226-229 ◽  
Author(s):  
Kishore Shetty
Keyword(s):  
Case Report ◽  
Antiretroviral Therapy ◽  
Highly Active Antiretroviral Therapy ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Positive Patient ◽  
Hiv Positive ◽  
Review Of The Literature ◽  
Highly Active

Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients

AIDS ◽  
2000 ◽  
Vol 14 (8) ◽  
pp. 987-993 ◽  
Author(s):  
Caroline Dupont ◽  
Emmanuelle Vasseur ◽  
Alain Beauchet ◽  
Philippe Aegerter ◽  
Huguette Berthé ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Highly Active Antiretroviral Therapy ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Hiv Positive ◽  
Term Efficacy ◽  
Highly Active

Classic Kaposi's sarcoma on the glans penis only: Case report

1997 ◽  
Vol 64 (1) ◽  
pp. 134-135
Author(s):  
E. Gastaldi ◽  
S. Benvenuti ◽  
B. Mennini ◽  
M. Iacoviello ◽  
M. Caviglione ◽  
...  
Keyword(s):  
Case Report ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Positive Patient ◽  
Glans Penis ◽  
Hiv Positive ◽  
Partial Penectomy

The Authors report a case of Kaposi's sarcoma presenting on the glans penis only in a non-HIV positive patient, who had not been treated with immuno-suppressive drugs. In our experience and according to a review of specific literature, choice treatment would seem to be a radiotherapeutic approach followed by partial penectomy in the event of recurrence.

Kaposi's sarcoma associated with highly active antiretroviral therapy

2005 ◽  
Vol 16 (8) ◽  
pp. 583-583
Author(s):  
Heidi M Crane ◽  
Heike Deubner ◽  
Jane C Huang ◽  
Paul E Swanson ◽  
Robert D Harrington
Keyword(s):  
Antiretroviral Therapy ◽  
Highly Active Antiretroviral Therapy ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Highly Active

scholarly journals Phase II Study of Bevacizumab in Patients With HIV-Associated Kaposi's Sarcoma Receiving Antiretroviral Therapy

2012 ◽  
Vol 30 (13) ◽  
pp. 1476-1483 ◽  
Author(s):  
Thomas S. Uldrick ◽  
Kathleen M. Wyvill ◽  
Pallavi Kumar ◽  
Deirdre O'Mahony ◽  
Wendy Bernstein ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Highly Active Antiretroviral Therapy ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Complete Response ◽  
Median Number ◽  
Primary Objective ◽  
Cytotoxic Agents ◽  
Prior Chemotherapy ◽  
Highly Active

Purpose Alternatives to cytotoxic agents are desirable for patients with HIV-associated Kaposi's sarcoma (KS). Vascular endothelial growth factor-A (VEGF-A) contributes to KS pathogenesis. We evaluated the humanized anti–VEGF-A monoclonal antibody, bevacizumab, in patients with HIV-KS. Patients and Methods Patients with HIV-KS who either experienced progression while receiving highly active antiretroviral therapy (HAART) for at least 1 month or did not regress despite HAART for at least 4 months were administered bevacizumab 15 mg/kg intravenously on days 1 and 8 and then every 3 weeks. The primary objective was assessment of antitumor activity using modified AIDS Clinical Trial Group (ACTG) criteria for HIV-KS. HIV-uninfected patients were also eligible and observed separately. Results Seventeen HIV-infected patients were enrolled. Fourteen patients had been receiving effective HAART for at least 6 months (median, 1 year). Thirteen patients had advanced disease (ACTG T1), 13 patients had received prior chemotherapy for KS, and seven patients had CD4 count less than 200 cells/μL. Median number of cycles was 10 (range, 1 to 37 cycles); median follow-up was 8.3 months (range, 3 to 36 months). Of 16 assessable patients, best tumor responses observed were complete response (CR) in three patients (19%), partial response (PR) in two patients (12%), stable disease in nine patients (56%), and progressive disease in two patients (12%). Overall response rate (CR + PR) was 31% (95% CI, 11% to 58.7%). Four of five responders had received prior chemotherapy for KS. Over 202 cycles, grade 3 to 4 adverse events at least possibly attributed to therapy included hypertension (n = 7), neutropenia (n = 5), cellulitis (n = 3), and headache (n = 2). Conclusion Bevacizumab is tolerated in patients with HIV-KS and has activity in a subset of patients.

Sign in / Sign up

Export Citation Format

Share Document